- Built to Serve: The Day That Reminds Us Why We Chose Dentistry
- Journalists Catch You Up on Fauci Hearing, Peptides, and Kids’ Caffeine Consumption
- CMS finalizes 2.3% hospital pay bump, mandatory joint replacement model: 9 things to know
- How ambulatory shifts are reshaping perioperative strategy
- Cyclosporiasis cases top 18,000: 3 updates
- How Allegheny Health Network Strengthened its Foundation for IV Compounding Safety with Automation and Standardization¹
- Health plan customer service reps have AI in their ear
- Centene’s buyouts could have a $315M+ price tag for the rest of the year
- Medicare pay cut sparks specialty battle over skin cancer care
- Cardiovascular Institute of New England provides notice of data incident
- CMS locks in 2.3% inpatient hospital base pay increase, nudges back CJR-X Model start date
- Why autonomy — not just capital — is winning over cardiologists
- The $36 vs. $95 problem: How RVU negotiations are skewing physician pay
- Mississippi hospital board member, former CEO remembered as advocate for rural communities
- Pennsylvania SUD treatment locator reaches 146K users
- Top 10 dental, DSO stories in July
- Ohio youth treatment facility faces scrutiny over reported abuse: 8 notes
- What dental leaders told us in July
- Urban hospital closures and net change, by state
- Nebraska launches dashboard tracking rural health funds
- ADSO sues Colorado Dental Board over practice ownership rule
- New patient acquisition is the top growth driver for dental practices: Report
- 20 new behavioral health projects to know
- Nurses, patients protest North Star Health Alliance ASC closure
- No Surprises Act under attack by payers: 8 things to know
- Dental staffing wages up 23% since 2021: ADA
- AtlantiCare appoints anesthesiology, gastroenterology physician leaders
- Consumer dental spending up 24% over 10 years: 5 stats to know
- Baylor Scott & White joint venture expands outpatient behavioral health services
- 5 DSOs making headlines
- VA to explore GLP-1 treatment for alcohol use disorder: 4 notes
- A $5B wave of M&A hits the ASC industry
- FTC Sues Hims & Hers Over Health Privacy And Billing Practices
- 145 physician medical groups led all healthcare M&A sectors in Q1
- 10 new ASCs in July
- Healthcare exec, telemedicine company owner sentenced for $35M DME fraud scheme
- Amylyx demystifies post-bariatric hypoglycemia with patient education website
- What Dad Eats Before Conception May Influence Baby's Health
- Family History Plays Role In Genetic Risk For Breast Cancer, Researchers Find
- A look at employers' attitudes toward ICHRAs
- Revised 340B Rebate Model Pilot Program moves forward, despite provider pushback
- Function Health lands $450M in growth financing to scale tech-enabled preventive health
- Daiichi Sankyo flags accounting error, as shares tank despite revenue beat
- AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market
- Op-ed: Hospitals on the edge, a time for CMS to do no harm
- Daily Routine Key To Good Health, Study Says
- Alignment Healthcare boasts 32% revenue jump in Q2, lifts 2026 outlook
- Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
- Psilocybin Therapy Helps Ease Veterans' Severe PTSD, Pilot Study Finds
- Newsom Reverses On Long-Sought Paid Leave Benefit For California Teachers
- Nicotine Levels Are Rising Among Teens Who Vape, New Study Warns
- The Newest Federally Recognized Tribe Wants Better Healthcare. It May Be On Its Own.
- They Worked To Protect Public Health. Now They Want the Public’s Votes.
- 27 new behavioral health study findings to know
- 21 state behavioral health policy updates
- What will fuel the next wave of DSO growth
- Dentists’ biggest staffing headaches
- Shionogi makes the call on COVID pill Xocova TV spot
- Psilocybin-assisted therapy reduced PTSD symptoms: 3 notes
- Fierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod
- Psychedelics, peptides and GLP-1s
- How 'physician-led' care team models tackle primary care's workforce problem
- How 7 systems divert behavioral health patients from the ED
- WellSpan Health, Hippocratic AI ink ‘multi-year’ partnership with plans to co-develop clinical AI agents
- Kaiser faces complaint over automated behavioral health triage system
- Free research hub Nila aims to demystify menopause, other hormone conditions
- Scientists Defend Fauci's Pandemic Work As Senate Hearing Turns Bitter
- Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie
- Study Questions Effectiveness of Antihistamines in Easing Eczema
- Vaping Is Likely Reshaping The Future Of Cancer In The US, Study Argues
- Weekly Rundown: Counsel Health rolls out white label AI care platform; Community Health Network launches MyChart AI assistant
- New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat
- Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026
- Waystar boosts 2026 outlook as AI-powered RCM solutions gain traction with providers
- YouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort
- Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic
- Sugar Consumption Early In Life Linked To Increased Dementia Risk, World War II-Era Data Show
- Work Stress Harming Middle-Age Sleep, Study Says
- RFK Jr.'s Gardasil litigation ties subject to fresh lawmaker scrutiny after Merck settlement
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
- Hospice's Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn
- Cell Phone Ownership Linked To Lower Reading Skills In Elementary Students
- Listen to the Latest ‘KFF Health News Minute’
- Medicaid Insurers’ Contracts on the Line in Tight Governor’s Race
- Abortion Drug Law in Louisiana Heightens Hemorrhage Risk for Pregnant Patients
- Teladoc Health trims 2026 revenue forecast amid challenges with BetterHelp insurance shift
- Cigna CEO: Express Scripts seeing 'significant early interest' from clients for new rebate-free PBM model
- Viatris runs into FDA roadblock after advertising on-the-go use of cystic fibrosis inhaler
- Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
- FTC sues Hims & Hers over data privacy, billing practices
- CMS' proposed 340B reimbursement cut—who wins, and who loses?
- Virtual care helps patients improve their gambling disorder symptoms, Birches Health finds
- Case Western Reserve University launches next-generation healthcare leadership program
- Lilly, Resilience commit $750M to boost US diabetes, obesity med production
- CMS ending Medicare Part D subsidy program
- Red Cross Declares Rare National Blood Supply Crisis Amid Summer Shortfall
- Not Just Pregnancy Fatigue: Could It Be Sleep Apnea?
- More Women Drinking During Pregnancy
- Wellstar Health System lays off 761 corporate, administrative staff
- Biogen flips '26 guidance from expected decline to sales increase
- Teva’s innovation engine offsets generics slump, leaving one analyst ‘shocked’ by Ajovy’s surge
- Talking To Your Baby? Eye Contact Is Key To Language Development, Experiment Shows
- Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026
- Leapfrog launches expanded ASC public reporting program
- Cyclospora Boosts Fears That Deadlier Foodborne Outbreaks Are Ahead
- DoorDash, GrubHub Delivering Junk Food To 1 In 4 Teens During School Hours
- Uninsured but Undaunted, a Surgical Patient Searched the Globe for a Deal
- Trump Has Quietly Throttled an Agency Devoted to the Safety of American Healthcare
- Hospice’s Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn
- Humana plans more market exits for 2027, CFO says
- PMCPA sanctions melatonin drugmaker over misleading information
- CG Life embraces next-gen era in merger with AI-native agency The Considered+AI
- How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval
- Fifth Death Reported In NYC Legionnaires' Disease Outbreak
- Many Young Adults Aren't Ready To Manage Their Own Healthcare, Poll Finds
- Can A Daily Multivitamin Help You Stay Active As You Age?
- Stellarus launches AI-powered health plan customer service representative copilot
- Prebiotic Soda Health Claims Questioned In New Nutrition Study
- Family-Based Childhood Obesity Program Helps Kids Cut Weight, Become Healthier
- To Afford Aging In Place, Older Adults Turn To 'Golden Girls' Housing
- Breakfast Can Help Teens Make Better Food Choices Throughout Their Day, Study Says
- Newsom Reverses on Long-Sought Paid Leave Benefit for Teachers in California
- FDA Panel Backs Two Peptides For Compounding, Rejects One
- How Accurate Are Photo-Based Calorie Apps? 4 Are Put To The Test
- Popular School Cafeteria Meals Need An Update To Meet Healthy Food Standards, Researchers Say
- Ovarian Syndrome Quadruples Heart Disease Risk In Women, Major Study Concludes
- Weed-Killing Chemical, Glyphosate, Linked To Premature Births In Humans, Study Says
- 'The Child Is Terrified': Doctors On Front Lines Of Measles Comeback Speak Out
- 'Yo-yo' Weight Loss Linked To Decline In Muscle Mass
- FDA Advisers Dismiss Safety Warnings, Back Four Peptide Treatments
- Frequent Marijuana Use Linked To Higher Stress Hormone Levels
- Back Pain? Try Swimming, Study Says
- Ozempic Cuts Down Calorie Intake For At Least A Year, Even If Hunger Returns, Trial Finds
- Money Problems Might Make Your Brain Old Before Its Time, Study Suggests
- Black MS Patients Dying Younger Than White Ones, Study Finds
- Headstands and Summervaults: A Statement on Crypto Vaults and Lending Strategies
- Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Seeking Public Comment on Seeking Public Capital: Remarks Before the Small Business Capital Formation Advisory Committee
- Remarks to the Small Business Capital Formation Advisory Committee
- Statement on Regulation E-Delivery
- Paper Taper: Statement on Proposed Regulation E-Delivery
- Statement on Proposed Regulation E-Delivery
- Senate HELP committee advances nominees for CDC director, HHS preparedness head
- Remarks before the American-Hellenic Chamber of Commerce
- Remarks at the Society for Corporate Governance Conference
- Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
- Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
- AdaptHealth Investigates Data Breach After Social Engineering Attack, Possible Link to ShinyHunters Emerges
- AdaptHealth Investigates Data Breach After Social Engineering Attack, Possible Link to ShinyHunters Emerges
- Statement on the 2026 Regulatory Agenda
Michigan healthcare freedom community forum
Costco does not break out their pharmacy sales from their quarter trillion dollar overall sales, but their 614 U.S. warehouses are a major player in pharmaceutical sales:
Costco Says It Will Not Sell Abortion Pill Mifepristone
The company attributes its decision to lack of demand.
By Aldgra Fredly - August 15, 2025Costco Wholesale said on Aug.14 that it would maintain its stance of not selling the abortion pill mifepristone at its U.S. pharmacies due to low customer demand.
Mifepristone is a drug that blocks progesterone, the hormone needed for sustaining pregnancy. The Food and Drug Administration (FDA) approved the drug in 2000 for terminating pregnancy through 10 weeks of gestation, stating on its website that mifepristone is safe when used properly.
“Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,” the retailer said in a statement to multiple news outlets.
The move comes amid campaigns against the pill from faith-based groups, including exchange-traded fund provider Inspire Investing and legal advocacy group Alliance Defending Freedom (ADF).
ADF legal counsel Michael Ross applauded Costco for its decision.
“Retailers like Costco keep their doors open by selling a lifetime of purchases to families, both large and small. They have nothing to gain and much to lose by becoming abortion dispensaries,” Ross said in a statement.
Students for Life America (SFLA) praised the move as “a stunning win for life,” saying that it hopes more companies would follow Costco’s policy.
“Costco Wholesale insists its reason was not based on pressure from groups like ours,” SFLA stated. “We at PLG [pro-life generation] never expected an acknowledgement or public change of corporate heart on record. But we would still like to commend the pro-life movement for speaking sense into Costco Wholesale, resulting in saving the lives of the preborn and women.”
In May, Health Secretary Robert F. Kennedy Jr. ordered the FDA to review mifepristone after an analysis found that nearly 11 percent of women who took the drug experienced serious adverse events, including sepsis and hemorrhaging.
That percentage is higher than the summary figure of less than 0.5 percent in clinical trials reported on the drug label, according to the Ethics and Public Policy Center, which published the analysis.
“I think the new data … is alarming, and clearly it indicates that at the very least, the label should be changed,” Kennedy said on May 14.
In July 2024, New York City Comptroller Brad Lander sent letters to Costco and other retailers to dispense the abortion drug in states where it is legal. In his letter to Costco, Lander warned that failing to do so could raise “significant investor concerns,” noting that the New York City Retirement Systems held $443.9 million in Costco stock.
Several investment advisers and corporate engagement consultants representing investors who held $56 million in Costco stock sent a letter to the retailer urging it not to sell mifepristone.
Their petition received support from thousands of investors and customers.
Costco got lit up by one of their home state Senators for their decision not to sell mifepristone:
https://thehill.com/policy/healthcare/5455913-patty-murray-costco-abortion-pill-mifepristone/
Senate Democrat rips Costco for ‘refusing to sell’ abortion pills
By Steff Danielle Thomas - August 16, 2025Sen. Patty Murray (D-Wash.) hammered Costco on Friday for appeasing “far-right extremists,” after the retailer said earlier this week that its pharmacies would not dispense the abortion medication mifepristone.
“I am deeply alarmed by news reports that Costco is refusing to sell safe, effective, and legal medication for no other reason than to appease the politics of anti-abortion fanatics,” Murray said in a statement following the news. “I refuse to stand by and allow far-right extremists to bully major corporations and dictate what medicine women can or cannot get access to.”
“Where it is legal, retailers and major pharmacies must absolutely make medication abortion available to the women who need it,” the Washington Democrat added.
Costco, in its Thursday announcement, explained that the decision came from a “lack of demand.”
“Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,” the company said, according to Reuters.
The decision comes after CVS and Walgreens announced last year that they received certification to provide the drug in states where abortion remains legal.
Murray pressed Costco to rescind its decision, warning that limiting access to mifepristone, one of two drugs used in medication abortion, is harmful to women’s health.
“Mifepristone is safe and effective—we cannot live in a world where the availability of women’s health care whipsaws back and forth based on the whims of extremists who want to deny women access to basic health care,” she wrote Friday. “I am demanding that Costco immediately reverse course—follow the science and the facts, not the demands of far-right anti-abortion extremists.”
The Supreme Court in a decision last year ruled unanimously that a group of anti-abortion doctors did not have the legal basis to challenge access to the pill.
Despite the ruling, Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Marty Makary are weighing a review of the abortion pill.
Murray questioned Makary during his Senate confirmation hearing on the proposal, as well as President Trump’s moves to gut staff at the FDA.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.





















